We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Diosynth Announces Agreement with ImmunoGen

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Diosynth Biotechnology, Inc. has announced the execution of an agreement with ImmunoGen, Inc. for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound.

Under this agreement, Diosynth Biotechnology will undertake technology transfer and conduct process and analytical development work related to production of ImmunoGen's huN901 antibody.

Diosynth will then manufacture - under cGMP - bulk huN901 antibody for ImmunoGen utilizing the Diosynth cell-culture, fed-batch technology.

ImmunoGen intends to use this antibody in the manufacture of future huN901-DM1 clinical materials.

“We are pleased to have been selected by ImmunoGen to produce antibody for their most-advanced product candidate,” stated Richard A. Basile, VP of Diosynth Sales and Marketing Group.

“ImmunoGen's choice of Diosynth further underscores the reputation of Diosynth Biotechnology as a leader in process development and the manufacture of cGMP-grade monoclonal antibody, consistent with our strength in the global biotherapeutics CMO arena.”